Cancer pharmacogenomics: Role of DNA repair genetic polymorphisms in individualizing cancer therapy

Molecular Diagnosis and Therapy

Volumn 11, Issue 6, 2007, Pages 361-380

  Gossage, Lucy ^a   Madhusudan, Srinivasan ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cancer, general; Genetic polymorphism; Pharmacogenomics

Indexed keywords

APURINIC ACID; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEOXYRIBONUCLEASE I; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NUCLEOTIDE; PLATINUM;

CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; DNA REPAIR; DRUG CYTOTOXICITY; EXCISION REPAIR; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MISMATCH REPAIR; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 37249019507     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256260     Document Type: Review

References (151)

1. Vesell ES. Pharmacogenetic perspectives gained from twin and family studies. Pharmacol Ther 1989; 41 (3): 535-52
2. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003 Feb 6; 348 (6): 538-49
3. Lee W, Lockhart AC, Kim RB, et al. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 2005 Feb; 10 (2): 104-11
4. Evans WE. Pharmacogenomics: marshalling the human genome to individualise drug therapy. Gut 2003 May; 52 Suppl. 2: ii10-8
5. Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 2005 Aug; 107 (2): 155-76
6. Yamayoshi Y, Iida E, Tanigawara Y. Cancer pharmacogenomics: international trends. Int J Clin Oncol 2005 Feb; 10 (1): 5-13
7. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, et al. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004; 73: 39-85
8. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004 Apr; 4 (4): 296-307
9. Dudas A, Chovanec M. DNA double-strand break repair by homologous recombination. Mutat Res 2004 Mar; 566 (2): 131-67
10. Bassing CH, Alt FW. The cellular response to general and programmed DNA double strand breaks. DNA Repair (Amst) 2004 Aug-Sep; 3 (8-9): 781-96
11. Schofield MJ, Hsieh P. DNA mismatch repair: molecular mechanisms and biological function. Annu Rev Microbiol 2003; 57: 579-608
12. Lees-Miller SP, Meek K. Repair of DNA double strand breaks by non-homologous end joining. Biochimie 2003 Nov; 85 (11): 1161-73
13. Dianov GL, Sleeth KM, Dianova II, et al. Repair of abasic sites in DNA. Mutat Res 2003 Oct 29; 531 (1-2): 157-63
14. Costa RM, Chigancas V, Galhardo Rda S, et al. The eukaryotic nucleotide excision repair pathway. Biochimie 2003 Nov; 85 (11): 1083-99
15. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003 Mar 15; 21 (6): 1174-9
16. Farivar AS, McCourtie AS, MacKinnon-Patterson BC, et al. Poly (ADP) ribose polymerase inhibition improves rat cardiac allograft survival. Ann Thorac Surg 2005 Sep; 80 (3): 950-6
17. Bouchard VJ, Rouleau M, Poirier GG. PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol 2003 Jun; 31 (6): 446-54
18. Allinson SL, Dianova II, Dianov GL, et al. Poly(ADP-ribose) polymerase in base excision repair: always engaged, but not essential for DNA damage processing. Acta Biochim Pol 2003; 50 (1): 169-79
19. Kraus WL, Lis JT. PARP goes transcription. Cell 2003 Jun 13; 113 (6): 677-83
20. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001 May 17; 411 (6835): 366-74
21. Brookes AJ. The essence of SNPs. Gene 1999 Jul 8; 234 (2): 177-86
22. Wilson 3rd DM, Bohr VA. The mechanics of base excision repair, and its relationship to aging and disease. DNA Repair (Amst) 2007 Apr 1; 6 (4): 544-59
23. Almeida KH, Sobol RW. A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA Repair (Amst) 2007 Jun 1; 6 (6): 695-711
24. Li D, Li Y, Jiao L, et al. Effects of base excision repair gene polymorphisms on pancreatic cancer survival. Int J Cancer 2007 Apr 15; 120 (8): 1748-54
25. Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007 May; 56 (2): 281-8
26. Suh KW, Kim JH, Kimdo Y, et al. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann Surg Oncol 2006 Nov; 13 (11): 1379-85
27. Stoehlmacher J, Ghaderi V, Iobal S, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 2001 Jul-Aug; 21 (4B): 3075-9
28. Wang ZH, Miao XP, Tan W, et al. Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer [in Chinese]. Ai Zheng 2004 Aug; 23 (8): 865-8
29. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004 Jul 1; 22 (13): 2594-601
30. de las Penas R, Sanchez-Ronco M, Alberola V, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006 Apr; 17 (4): 668-75
31. Wu X, Gu J, Wu TT, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006 Aug 10; 24 (23): 3789-98
32. Moreno V, Gemignani F, Landi S, et al. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res 2006 Apr 1; 12 (7 Pt 1): 2101-8
33. Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004 Jul 19; 91 (2): 344-54
34. Wei J, Liu BR, Zou Z, et al. ERCC1 mRNA expression and XRCC1 polymorphism as predictive factors for overall survival in gastric cancer patients receiving platinum based chemotherapy [abstract]. 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 2007 Jun 20. J Clin Oncol 2007; 25 (18S): 2512
35. Ruzzo A, Graziano F, Kawakami K, et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 2006 Apr 20; 24 (12): 1883-91
36. Jaremko M, Justenhoven C, Schroth W, et al. Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer. Pharmacogenet Genomics 2007 Jul; 17 (7): 529-38
37. Bewick MA, Conlon MS, Lafrenie RM. Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol 2006 Dec 20; 24 (36): 5645-51
38. Sakano S, Wada T, Matsumoto H, et al. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer 2006 Sep 4; 95 (5): 561-70
39. Fishel ML, Kelley MR. The DNA base excision repair protein APE1/REF-1 as a therapeutic and chemopreventive target. Mol Aspects Med 2007 Jun-Aug; 28 (3-4): 375-95
40. Hadi MZ, Coleman MA, Fidelis K, et al. Functional characterization of Ape1 variants identified in the human population. Nucleic Acids Res 2000 Oct 15; 28 (20): 3871-9
41. Hung RJ, Hall J, Brennan P, et al. Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol. 2005 Nov 15; 162 (10): 925-42
42. Takanami T, Nakamura J, Kubota Y, et al. The Arg280His polymorphism in X-ray repair cross-complementing gene 1 impairs DNA repair ability. Mutat Res 2005 Apr 4; 582 (1-2): 135-45
43. Park CJ, Choi BS. The protein shuffle. Sequential interactions among components of the human nucleotide excision repair pathway. FEBS J 2006 Apr; 273 (8): 1600-8
44. Reardon JT, Sancar A. Nucleotide excision repair. Prog Nucleic Acid Res Mol Biol 2005; 79: 183-235
45. Hanawalt PC. Subpathways of nucleotide excision repair and their regulation. Oncogene 2002 Dec 16; 21 (58): 8949-56
46. Gillet LC, Scharer OD. Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev 2006 Feb; 106 (2): 253-76
47. Zarate RN, Arias F, Bandres E, et al. Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy. World J Gastroenterol 2006 Oct 7; 12 (37): 6032-6
48. Park DJ, Stoehlmacher J, Zhang W, et al. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001 Dec 15; 61 (24): 8654-8
49. Yuan P, Miao XP, Zhang XM, et al. Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer [in Chinese]. Zhonghua Yi Xue Za Zhi 2005 Apr 13; 85 (14): 972-5
50. Camps C, Sarries C, Roig B, et al. Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin- treated advanced non-small-cell lung cancer patients. Clin Lung Cancer 2003 Jan; 4 (4): 237-41
51. Chen H, Shao C, Shi H, et al. Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-a-vis chemotherapy drug cytotoxicity in human glioma. J Neurooncol 2007 May; 82 (3): 257-62
52. Allan JM, Smith AG, Wheatley K, et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 2004 Dec 15; 104 (13): 3872-7
53. Kuptsova N, Kopecky KJ, Godwin J, et al. Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. Blood 2007 May 1; 109 (9): 3936-44
54. Vangsted A, Gimsing P, Klausen TW, et al. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation. Int J Cancer 2007 Mar 1; 120 (5): 1036-45
55. Rosell R, Taron M, Camps C, et al. Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today (Barc) 2003 Oct; 39 (10): 775-86
56. Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004 Jun; 44 (3): 311-6
57. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004 Aug; 15 (8): 1194-203
58. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004 Aug 1; 10 (15): 4939-43
59. Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005 Sep 1; 11 (17): 6212-7
60. Park DJ, Zhang W, Stoehlmacher J, et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003 Mar; 1 (3): 162-6
61. Kang S, Ju W, Kim JW, et al. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 2006 Jun 30; 38 (3): 320-4
62. Yuan P, Miao XP, Zhang XM, et al. Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy [in Chinese]. Ai Zheng 2005 Dec; 24 (12): 1510-3
63. Gu J, Zhao H, Dinney CP, et al. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res 2005 Feb 15; 11 (4): 1408-15
64. Lunn RM, Helzlsouer KJ, Parshad R, et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000 Apr; 21 (4): 551-5
65. Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001 Feb 15; 61 (4): 1354-7
66. Dybdahl M, Vogel U, Frentz G, et al. Polymorphisms in the DNA repair gene XPD: correlations with risk and age at onset of basal cell carcinoma. Cancer Epidemiol Biomarkers Prev 1999 Jan; 8 (1): 77-81
67. Qiao Y, Spitz MR, Shen H, et al. Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 2002 Feb; 23 (2): 295-9
68. Seker H, Butkiewicz D, Bowman ED, et al. Functional significance of XPD polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype. Cancer Res 2001 Oct 15; 61 (20): 7430-4
69. Rzeszowska-Wolny J, Polanska J, Pietrowska M, et al. Influence of polymorphisms in DNA repair genes XPD, XRCC1 and MGMT on DNA damage induced by gamma radiation and its repair in lymphocytes in vitro. Radiat Res 2005 Aug; 164 (2): 132-40
70. Le Morvan V, Bellott R, Moisan F, et al. Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-a-vis the NCI-60 panel. Pharmacogenomics 2006 Sep; 7 (6): 843-52
71. Gossage L, Madhusudan S. Current status of excision repair cross complementing enzyme (ERCC1) in cancer. Cancer Treat Rev 2007 Oct; 33 (6): 565-77
72. Petty WJ, Knight SN, Mosley L, et al. A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer. J Thorac Oncol 2007 Mar; 2 (3): 197-202
73. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998 Feb 15; 58 (4): 604-8
74. Chen P, Wiencke J, Aldape K, et al. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 2000 Aug; 9 (8): 843-7
75. Yu JJ, Lee KB, Mu C, et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000 Mar; 16 (3): 555-60
76. Wu X, Zhao H, Wei Q, et al. XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. Carcinogenesis 2003 Mar; 24 (3): 505-9
77. Graves RJ, Li BF, Swann PF. Repair of synthetic oligonucleotides containing O6-methylguanine, O6-ethylguanine and O4-methylthymine, by O6-alkylguanine-DNA alkyltransferase. IARC Sci Publ 1987; (84): 41-3
78. Gonzaga PE, Brent TP. Affinity purification and characterization of human O6-alkylguanine-DNA alkyltransferase complexed with BCNU-treated, synthetic oligonucleotide. Nucleic Acids Res 1989 Aug 25; 17 (16): 6581-90
79. Esteller M, Herman JG. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 2004 Jan 8; 23 (1): 1-8
80. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000 Nov 9; 343 (19): 1350-4
81. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004 Aug 1; 10 (15): 4933-8
82. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005 Mar 10; 352 (10): 997-1003
83. Sabharwal A, Middleton MR. Exploiting the role of O6-methylguanine-DNA- methyltransferase (MGMT) in cancer therapy. Curr Opin Pharmacol 2006 Aug; 6 (4): 355-63
84. Wiencke JK, Aldape K, McMillan A, et al. Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. Cancer Epidemiol Biomarkers Prev 2005 Jul; 14 (7): 1774-83
85. Yang M, Coles BF, Caporaso NE, et al. Lack of association between Caucasian lung cancer risk and O6-methylguanine-DNA methyltransferase-codon 178 genetic polymorphism. Lung Cancer 2004 Jun; 44 (3): 281-6
86. Abe M, Inoue R, Suzuki T. A convenient method for genotyping of human O6-methylguanine-DNA methyltransferase polymorphism. Jpn J Hum Genet 1997 Sep; 42 (3): 425-8
87. Otsuka M, Abe M, Nakabeppu Y, et al. Polymorphism in the human O6-methylguanine-DNA methyltransferase gene detected by PCR-SSCP analysis. Pharmacogenetics 1996 Aug; 6 (4): 361-3
88. Imai Y, Oda H, Nakatsuru Y, et al. A polymorphism at codon 160 of human O6-methylguanine-DNA methyltransferase gene in young patients with adult type cancers and functional assay. Carcinogenesis 1995 Oct; 16 (10): 2441-5
89. Schwarzl SM, Smith JC, Kaina B, et al. Molecular modeling of O6-methylguanine-DNA methyltransferase mutant proteins encoded by single nucleotide polymorphisms. Int J Mol Med 2005 Oct; 16 (4): 553-7
90. Ma S, Egyhazi S, Ueno T, et al. O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br J Cancer 2003 Oct 20; 89 (8): 1517-23
91. Edara S, Kanugula S, Goodtzova K, et al. Resistance of the human O6-alkylguanine-DNA alkyltransferase containing arginine at codon 160 to inactivation by O6-benzylguanine. Cancer Res 1996 Dec 15; 56 (24): 5571-5
92. Pegg AE, Kanugula S, Edara S, et al. Reaction of O6-benzylguanine- resistant mutants of human O6-alkylguanine-DNA alkyltransferase with O6-benzylguanine in oligodeoxyribonucleotides. J Biol Chem 1998 May 1; 273 (18): 10863-7
93. Xu-Welliver M, Leitao J, Kanugula S, et al. Role of codon 160 in the sensitivity of human O6-alkylguanine-DNA alkyltransferase to O6-benzylguanine. Biochem Pharmacol 1999 Oct 15; 58 (8): 1279-85
94. Margison GP, Heighway J, Pearson S, et al. Quantitative trait locus analysis reveals two intragenic sites that influence O6-alkylguanine-DNA alkyltransferase activity in peripheral blood mononuclear cells. Carcinogenesis 2005 Aug; 26 (8): 1473-80
95. Drummond JT, Anthoney A, Brown R, et al. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996 Aug 16; 271 (33): 19645-8
96. Friedman HS, Johnson SP, Dong Q, et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 1997 Jul 15; 57 (14): 2933-6
97. Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 1996 Dec 1; 56 (23): 5375-9
98. Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996 Jul 1; 56 (13): 3087-90
99. Aebi S, Fink D, Gordon R, et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 1997 Oct; 3 (10): 1763-7
100. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001 Mar; 27 (3): 247-54
101. Sonoda E, Hochegger H, Saberi A, et al. Differential usage of non-homologous end-joining and homologous recombination in double strand break repair. DNA Repair (Amst) 2006 Sep 8; 5 (9-10): 1021-9
102. Wyman C, Kanaar R. DNA double-strand break repair: all's well that ends well. Annu Rev Genet 2006; 40: 363-83
103. Ruttan CC, Glickman BW. Coding variants in human double-strand break DNA repair genes. Mutat Res 2002 Nov 30; 509 (1-2): 175-200
104. Chappuis PO, Goffin J, Wong N, et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002 Aug; 39 (8): 608-10
105. Goffin JR, Chappuis PO, Begin LR, et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 2003 Feb 1; 97 (3): 527-36
106. Delaloge S, Pautier P, Kloos I. BRCA1-linked breast cancer (BC) is highly more chemosensitive than its BRCA2-linked or sporadic counterparts [abstract 120]. 27th Congress of the European Society of Medical Oncology; 2002 Oct 18-22; Nice.
107. Kirova YM, Stoppa-Lyonnet D, Savignoni A, et al. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005 Oct; 41 (15): 2304-11
108. Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003 May 1; 97 (9): 2187-95
109. Li D, Liu H, Jiao L, et al. Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. Cancer Res 2006 Mar 15; 66 (6): 3323-30
110. Li D, Frazier M, Evans DB, et al. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol 2006 Apr 10; 24 (11): 1720-8
111. Meier M, den Boer ML, Hall AG, et al. Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia. Leukemia 2005 Nov; 19 (11): 1887-95
112. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000 Nov 23; 408 (6811): 429-32
113. Wang Y, Cortez D, Yazdi P, et al. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000 Apr 15; 14 (8): 927-39
114. Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004 Nov 17; 96 (22): 1659-68
115. James CR, Quinn JE, Mullan PB, et al. BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist 2007 Feb; 12 (2): 142-50
116. Rafii S, O'Regan P, Xinarianos G, et al. A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer. Hum Mol Genet 2002 Jun 1; 11 (12): 1433-8
117. Danoy P, Sonoda E, Lathrop M, et al. A naturally occurring genetic variant of human XRCC2 (R188H) confers increased resistance to cisplatin-induced DNA damage. Biochem Biophys Res Commun 2007 Jan 19; 352 (3): 763-8
118. Gurska S, Farkasova T, Gabelova A. Radiosensitivity of cervical cancer cell lines: the impact of polymorphisms in DNA repair genes. Neoplasma 2007; 54 (3): 195-201
119. Hu JJ, Smith TR, Miller MS, et al. Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 2001 Jun; 22 (6): 917-22
120. Alsbeih G, El-Sebaie M, Al-Harbi N, et al. Radiosensitivity of human fibroblasts is associated with amino acid substitution variants in susceptible genes and correlates with the number of risk alleles. Int J Radiat Oncol Biol Phys 2007 May 1; 68 (1): 229-35
121. Araujo FD, Pierce AJ, Stark JM, et al. Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks. Oncogene 2002 Jun 13; 21 (26): 4176-80
122. Carles J, Monzo M, Amat M, et al. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006 Nov 15; 66 (4): 1022-30
123. Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 2005 Feb 15; 11 (4): 1534-8
124. Chang-Claude J, Popanda O, Tan XL, et al. Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 2005 Jul 1; 11 (13): 4802-9
125. Moullan N, Cox DG, Angele S, et al. Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev 2003 Nov; 12 (11 Pt 1): 1168-74
126. Popanda O, Tan XL, Ambrosone CB, et al. Genetic polymorphisms in the DNA double-strand break repair genes XRCC3, XRCC2, and NBS1 are not associated with acute side effects of radiotherapy in breast cancer patients. Cancer Epidemiol Biomarkers Prev 2006 May; 15 (5): 1048-50
127. Andreassen CN, Alsner J, Overgaard M, et al. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 2003 Nov; 69 (2): 127-35
128. Andreassen CN, Alsner J, Overgaard M, et al. Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM: a study based on DNA from formalin fixed paraffin embedded tissue samples. Int J Radiat Biol 2006 Aug; 82 (8): 577-86
129. Damaraju S, Murray D, Dufour J, et al. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 2006 Apr 15; 12 (8): 2545-54
130. De Ruyck K, Van Eijkeren M, Claes K, et al. Radiation-induced damage to normal tissues after radiotherapy in patients treated for gynecologic tumors: association with single nucleotide polymorphisms in XRCC1, XRCC3, and OGG1 genes and in vitro chromosomal radiosensitivity in lymphocytes. Int J Radiat Oncol Biol Phys 2005 Jul 15; 62 (4): 1140-9
131. De Ruyck K, Wilding CS, Van Eijkeren M, et al. Microsatellite polymorphisms in DNA repair genes XRCC1, XRCC3 and XRCC5 in patients with gynecological tumors: association with late clinical radiosensitivity and cancer incidence. Radiat Res 2005 Sep; 164 (3): 237-44
132. Shanley S, McReynolds K, Ardern-Jones A, et al. Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res 2006 Dec 1; 12 (23): 7025-32
133. Shanley S, McReynolds K, Ardern-Jones A, et al. Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clin Cancer Res 2006 Dec 1; 12 (23): 7033-8
134. Angele S, Romestaing P, Moullan N, et al. ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res 2003 Dec 15; 63 (24): 8717-25
135. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995 Mar 30; 31 (5): 1341-6
136. Ho AY, Atencio DP, Peters S, et al. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys 2006 Jul 1; 65 (3): 646-55
137. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 2003 Mar; 3 (3): 155-68
138. Su Y, Swift M. Mortality rates among carriers of ataxia-telangiectasia mutant alleles. Ann Intern Med 2000 Nov 21; 133 (10): 770-8
139. Gilad S, Khosravi R, Shkedy D, et al. Predominance of null mutations in ataxia-telangiectasia. Hum Mol Genet 1996 Apr; 5 (4): 433-9
140. Stankovic T, Kidd AM, Sutcliffe A, et al. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet 1998 Feb; 62 (2): 334-45
141. Gutierrez-Enriquez S, Fernet M, Dork T, et al. Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosomes Cancer 2004 Jun; 40 (2): 109-19
142. Varghese S, Schmidt-Ullrich RK, Dritschilo A, et al. Enhanced radiation late effects and cellular radiation sensitivity in an ATM heterozygous breast cancer patient. Radiat Oncol Investig 1999; 7 (4): 231-7
143. Oppitz U, Bernthaler U, Schindler D, et al. Sequence analysis of the ATM gene in 20 patients with RTOG grade 3 or 4 acute and/or late tissue radiation side effects. Int J Radiat Oncol Biol Phys 1999 Jul 15; 44 (5): 981-8
144. Iannuzzi CM, Atencio DP, Green S, et al. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys 2002 Mar 1; 52 (3): 606-13
145. Hall EJ, Schiff PB, Hanks GE, et al. A preliminary report: frequency of A-T heterozygotes among prostate cancer patients with severe late responses to radiation therapy. Cancer J Sci Am 1998 Nov-Dec; 4 (6): 385-9
146. Andreassen CN, Alsner J, Overgaard J, et al. TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol 2005 Apr; 75 (1): 18-21
147. Bremer M, Klopper K, Yamini P, et al. Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: no observation of increased radiation-induced acute or late effects. Radiother Oncol 2003 Nov; 69 (2): 155-60
148. Price EA, Bourne SL, Radbourne R, et al. Rare microsatellite polymorphisms in the DNA repair genes XRCC1, XRCC3 and XRCC5 associated with cancer in patients of varying radiosensitivity. Somat Cell Mol Genet 1997 Jul; 23 (4): 237-47
149. Leong T, Whitty J, Keilar M, et al. Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients. Int J Radiat Oncol Biol Phys 2000 Nov 1; 48 (4): 959-65
150. Severin DM, Leong T, Cassidy B, et al. Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients. Int J Radiat Oncol Biol Phys 2001 Aug 1; 50 (5): 1323-31
151. Asper Biotech. DNA repair genetic testing [online]. Available from URL: http://www.asperbio.com/DNArepair.htm [Accessed 2007 Dec 4]